| Fecal Microbiota Transplant for Neuroblastoma in a Single Patient (NCT07223606) | ProgenaBiome | |
| F18 DCFPyL PET/CT in Imaging Participants With Recurrent Prostate Cancer (NCT03501940) | Andrei Iagaru | |
| Expanded Access for BLZ-100 (Tozuleristide) (NCT04343274) | Blaze Bioscience Inc. | |
| Experimental Expanded Access Treatment With Convalescent Plasma for the Treatment of Patients With COVID-19 (NCT04445207) | Jonathan Gerber | |
| A Single-Arm, Expanded Access Study of Zanubrutinib in Participants With B-cell Malignancies (NCT04052854) | BeiGene | |
| Treatment Use of 3,4 Diaminopyridine in Congenital Myasthenia (NCT03062631) | Ricardo Maselli | |
| MAP to Provide Access to Nilotinib, for Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (NCT04559555) | Novartis Pharmaceuticals | |
| MAP to Provide Access to Ruxolitinib, for Patients With Polycythemia Vera (NCT05269771) | Novartis Pharmaceuticals | |
| Protocol to Allow Continued Access of Ficlatuzumab to P05538 Patient (NCT02090127) | AVEO Pharmaceuticals, Inc. | |
| Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy (NCT02312037) | Pfizer | |
| Expanded Access Program With Pevonedistat (Given With Azacitidine) for Adults With Higher-risk Myelodysplastic Syndromes (NCT04484363) | Takeda | |
| 131I-omburtamab for the Treatment of Central Nervous System/Leptomeningeal Neoplasms in Children and Young Adults (NCT05064306) | Memorial Sloan Kettering Cancer Center | |
| Individual Patient Expanded Access-Glembatumumab Vedotin (NCT03067935) | Celldex Therapeutics | |
| Evaluating the Use of Polymyxin B Cartridge Hemoperfusion for Patients With Septic Shock and COVID 19 (NCT04352985) | Spectral Diagnostics (US) Inc. | |
| "Individual Patient Expanded Access IND to Treat Primary Lateral Sclerosis" (NCT04825613) | Hope Biosciences Research Foundation | |
| Managed Access Program to Provide Alpelisib for Patients With HR+ Advanced or Metastatic Breast Cancer (NCT03706573) | Novartis Pharmaceuticals | |
| 89Zr-DFO-girentuximab Expanded Access Program (EAP) (NCT06090331) | Telix Pharmaceuticals (Innovations) Pty Limited | |
| An Expanded Access Study of Bemarituzumab (FPA144) for a Single Patient With Recurrent Bladder Cancer (NCT03801278) | Five Prime Therapeutics, Inc. | |
| SurVaxM Expanded Access Protocol (NCT04802447) | Roswell Park Cancer Institute | |
| Expanded Access Program for Avapritinib (NCT04714086) | Blueprint Medicines Corporation | |
| Individual Patient Expanded Access for AB-SA01, an Investigational Anti-Staphylococcus Aureus Bacteriophage Therapeutic (NCT03395769) | Armata Pharmaceuticals, Inc. | |
| Expanded Access of Onvansertib With FOLFIRI and Bevacizumab for the Second-Line Treatment of Participants With KRAS-Mutated Metastatic Colorectal Cancer (NCT04446793) | Cardiff Oncology | |
| Safety and Efficacy of Autologous Concentrated Bone Marrow Aspirate for Critical Limb Ischemia - Continued Access (NCT02474121) | Zimmer Biomet | |
| Expanded Access Use of Derazantinib for Advanced Intrahepatic Cholangiocarcinoma (iCCA) With FGFR Genomic Alterations (NCT04087876) | Basilea Pharmaceutica | |
| Expanded Access Protocol for Subjects With Relapsed or Refractory Advanced Solid Tumors Receiving TJ210001 (NCT05511350) | I-Mab Biopharma US Limited | |
| Expanded Access to Risankizumab (NCT03914261) | AbbVie | |
| Arkansas Expanded Access COVID-19 Convalescent Plasma Treatment Program (NCT04363034) | University of Arkansas | |
| Therasphere for Unresectable Primary or Secondary Liver Neoplasia (NCT02960620) | H. Lee Moffitt Cancer Center and Research Institute | |
| Expanded Access to ABBV-8E12 (NCT03744546) | AbbVie | |
| Expanded Access With Trappsol(R) Cyclo (TM) for an Individual Patient With Late Onset Alzheimer's Disease (NCT03624842) | Cyclo Therapeutics, Inc. | |
| Pilot Trial of HER-2/Neu Pulsed DC1 Vaccine for Patients With HER-2 Positive Metastatic Cancer (NCT02473653) | University of Pennsylvania | |
| Individual Patient Expanded Access IND of Autologous HB-adMSCs for the Treatment of Systemic Lupus Erythematosus (SLE) (NCT04907175) | Hope Biosciences Research Foundation | |
| Expanded Access Program of Ruxolitinib for the Emergency Treatment of Cytokine Storm From COVID-19 Infection (NCT04355793) | Incyte Corporation | |
| Expanded Access to SUVN-G3031 (Samelisant) for the Treatment of Subjects With Narcolepsy (NCT05530447) | Suven Life Sciences Limited | |
| Odevixibat for the Treatment of Progressive Familial Intrahepatic Cholestasis (NCT04483531) | Albireo | |
| Naxitamab and GM-CSF in People With Neuroblastoma (NCT04501757) | Memorial Sloan Kettering Cancer Center | |
| Sildenafil Therapy For Subjects Who Derive Clinical Benefit From Continued Treatment With Sildenafil (NCT01897740) | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | |
| Expanded Access Protocol Using HBOC-201 (NCT02684474) | Johns Hopkins University | |
| Expanded Access for Abatacept (NCT05170672) | Bristol-Myers Squibb | |
| Compassionate Use of MitoGel in Upper Tract Urothelial Carcinoma (NCT02701023) | Jonsson Comprehensive Cancer Center | |
| CAP-1002 in Severe COVID-19 Disease (NCT04338347) | Capricor Inc. | |
| PRESERVE-Zenith® Branch Endovascular Graft-Iliac Bifurcation (NCT02475798) | Cook Research Incorporated | |
| Predictive Clinical Diagnosis of Rheumatoid Arthritis Flares Using Non-Invasive Infra-red Thermal Imaging and an AI/ML Algorithm (NCT05124990) | North Florida Foundation for Research and Education | |
| Olaparib Expanded Access Program for BRCA Mutated Platinum Sensitive Relapsed High Grade Epithelial Ovarian Cancer Patients in Japan (NCT03063710) | AstraZeneca | |
| Pre-approval Access for Janssen's COVID Vaccine VAC31518 for Treating Physician Use (NCT04817657) | Janssen Research & Development, LLC | |
| Abrocitinib Expanded Access Protocol in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (NCT04564755) | Pfizer | |
| Compassionate Use of Vidutolimod (NCT06063746) | Regeneron Pharmaceuticals | |
| Individual Patient Expanded Access Gilteritinib (ASP2215) (NCT03315299) | Etan Orgel | |
| Arbekacin Treatment of Adult Patients With Infections Caused by Multidrug-resistant Bacteria (NCT01659515) | U.S. Army Medical Research and Development Command | |
| Dichloroacetate Treatment of Congenital Lactic Acidosis Phase B: Expanded Access (NCT01797276) | University of Florida | |
| Zenith® Low Profile AAA Endovascular Graft (NCT02557659) | Cook Group Incorporated | |
| Compassionate Use of SOM230 for Hyperinsulinemic/Hypoglycemia (NCT02835131) | Montefiore Medical Center | |
| McKenzie Exercise Vs Harmonic Technique in Chronic Low Back Pain (NCT02178202) | University of Tehran | |
| Anifrolumab Early Access Program (NCT04750057) | AstraZeneca | |
| An Expanded Access Protocol for Sebelipase Alfa for Patients With Lysosomal Acid Lipase Deficiency (NCT02376751) | Alexion Pharmaceuticals, Inc. | |
| Single-Patient Expanded Access Protocol - RNA-LP in a Patient With Recurrent Osteosarcoma (NCT07560709) | University of Florida | |
| Progressive Keratoconus or Ectasia Treatment Plan (NCT01384773) | Stephen Trokel | |
| Emergency/Compassionate Use - AMPLATZER Duct Occluder (NCT00583583) | Abbott Medical Devices | |
| Expanded Access Treatment of Subjects With Critical Limb Ischemia (CLI) With Minor Tissue Loss Who Are Unsuitable for Revascularization (NCT03886506) | Pluristem Ltd. | |
| Talent Aortic Cuff Stent Graft System Compassionate Use Registry (NCT00604643) | Medtronic Cardiovascular | |
| Managed Access Program for Momelotinib in Myelofibrosis (NCT05582083) | GlaxoSmithKline | |
| Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies (NCT02822495) | Atara Biotherapeutics | |
| Lixivaptan in a Single Subject With Intractable Pain Due to Polycystic Kidney Disease (NCT03717181) | Palladio Biosciences | |
| Treatment of Drug Resistant Epilepsy (NCT02461706) | University of Florida | |
| Pulsed Inhaled Nitric Oxide for the Treatment of Patients With Mild or Moderate COVID-19 (NCT04358588) | Bellerophon | |
| Using Hypnotherapy For Dementia & Alzheimer's (NCT01435551) | Families To The Rescue | |
| Compassionate Use Individual Request Program for GSK525762 in NUT Midline Carcinoma (NCT03702036) | GlaxoSmithKline | |
| Starch-entrapped Microspheres [Nutrabiotix Fiber] for Gut Health (NCT01210625) | Rush University Medical Center | |
| Individual Patient Expanded Access IND of Hope Biosciences Autologous Adipose-derived Mesenchymal Stem Cells for Spinal Cord Injury (NCT04064957) | Hope Biosciences Research Foundation | |
| Treatment Use of Generex Oral-lyn™ in Patients With Diabetes (NCT00948493) | Generex Biotechnology Corp. | |
| Expanded Access Protocol: Repeated Administration of Nurown® (Autologous MSC-NTF Cells) for the Treatment of ALS (NCT04681118) | Brainstorm-Cell Therapeutics | |
| Expanded Use of G-CSF Mobilized Donor CD34+ Selected Cells for Allogeneic Transplantation (NCT02258490) | Emory University | |
| A Treatment Access Program To Provide Maraviroc To Eligible Adult Patients Completing A4001050 Study Until Commercial Availability Of Maraviroc (Celsentri) In India (NCT00992654) | ViiV Healthcare | |
| Compassionate Use of Omegaven IV Fat Emulsion (NCT02477345) | Northwell Health | |
| Convalescent Plasma in Hospitalized COVID-19 Patients (NCT05157165) | Azienda Socio Sanitaria Territoriale di Mantova | |
| Expanded Access Study of Melphalan With Delcath CS-PHP System in Patients With Ocular/Cutaneous Melanoma Mets to Liver (NCT01728051) | Delcath Systems Inc. | |
| Expanded Treatment Protocol for Adults With FLT3-ITD Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) to Receive Quizartinib (NCT03746912) | Daiichi Sankyo | |
| MAP Treatment Plan With Afinitor for Postmenopausal Women With Advanced HR+ Breast Cancer (NCT05108740) | Novartis Pharmaceuticals | |
| SARSCoV2 (COVID-19) Convalescent Plasma (CP) Expanded Access Protocol (EAP) (NCT04374370) | AdventHealth | |
| Tazemetostat Expanded Access Program for Adults With Epithelioid Sarcoma (NCT04225429) | Epizyme, Inc. | |
| Expanded Access to NanoPac (NCT03756311) | NanOlogy, LLC | |
| Sotrovimab Expanded Access Treatment Protocol (COVID-19) (NCT05235347) | Vir Biotechnology, Inc. | |
| Expanded Access for Fixed-Dose Combination of Nivolumab Plus Relatlimab (NCT05170685) | Bristol-Myers Squibb | |
| Expanded Access Program for Patients at Risk for Catheter-related Infections Who Are Not Eligible for DefenCath® Clinical Trials (NCT06707480) | CorMedix Therapeutics | |
| Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline High Grade Gliomas (NCT03134131) | Jazz Pharmaceuticals | |
| Expanded Access Protocol to Provide Patisiran to Patients With Transthyretin-mediated Amyloidosis With Cardiomyopathy (NCT05505838) | Alnylam Pharmaceuticals | |
| An Expanded Treatment Protocol of Panobinostat in Combination Therapy for Relapsed, and Relapsed and Refractory Multiple Myeloma (NCT02568943) | Novartis Pharmaceuticals | |
| An Open-Label Treatment Protocol With UX003 rhGUS Enzyme Replacement Therapy for an Advanced Stage MPS 7 Patient (NCT02097251) | Joyce Fox | |
| Expanded Access Use of INCB054329 to Treat a Single Patient With Metastatic Renal Cell Carcinoma (NCT03896815) | Incyte Corporation | |
| Study Comparing Pursestring Wound Closure vs Conventional Closure to Reverse Stoma of Colorectal Cancer Patients (NCT02564224) | Zhejiang University | |
| Paromomycin for Individuals With Uncomplicated Cutaneous Leishmaniasis (NCT01641796) | U.S. Army Medical Research and Development Command | |
| J-Valve Compassionate Use (NCT03876964) | JC Medical, Inc., an affiliate of Edwards Lifesciences LLC | |
| Expanded Access Program for RP in Adults (NCT06574997) | Ocugen | |
| Expanded Access Program of Nintedanib in Patients With Idiopathic Pulmonary Fibrosis (NCT02230982) | Boehringer Ingelheim | |
| Compassionate Use Protocol for PF-03084014 in Patients With Advanced Solid Tumor Malignancies (NCT02955446) | University of Colorado, Denver | |
| Expanded Access Program to Provide Bamlanivimab (LY3819253) for the Treatment of COVID-19 (NCT04603651) | Eli Lilly and Company | |
| Post Study Continuation of C7 for G1D (NCT02018302) | Juan Pascual | |
| AbioCor Implantable Replacement Heart (NCT00669357) | Abiomed Inc. | |
| Direct Antibiotic Delivery of Cefazolin Into Soft Tissue Infections Using Subcutaneous Injection and Ultrasonic Dispersion (NCT01238276) | Sonescence, Inc. | |
| Compassionate Use Arm - ABI541 ABI for 10 NF2 Patients (NCT02589912) | Massachusetts Eye and Ear Infirmary | |